Palonosetron: A second generation 5-hydroxytryptamine 3 receptor antagonist Palonosetron Navari

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 12, 2009, Pages 1577-1586

  Navari, Rudolph M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti emetics; Chemotherapy induced nausea and vomiting; Palonosetron; Serotonin receptor antagonists

Indexed keywords

APOMORPHINE; AZASETRON; CISPLATIN; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; MORPHINE; OLANZAPINE; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; RAMOSETRON; SEROTONIN ANTAGONIST; TROPISETRON;

ANOREXIA; AREA UNDER THE CURVE; BINDING AFFINITY; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DROWSINESS; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MEMORY; MOOD CHANGE; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; POSTMARKETING SURVEILLANCE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; SIDE EFFECT; SLEEP DISORDER; VOMITING; XEROSTOMIA;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; ISOQUINOLINES; NAUSEA; QUINUCLIDINES; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; VOMITING;

EID: 71049189175     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903407289     Document Type: Review

References (62)

1. Lachaine J, Yelle L, Kaizer L, et al. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Supp Cancer Ther 2005;2:181-187
2. Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15(5):497-503
3. Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5- Hydroxytryptamine-3 antiemetics. Cancer 2003;97:2880-2886
4. Grunberg SM, Deuson R, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics: perception versus reality. Cancer 2004;100:2261-2268
5. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 2005;13:80-84
6. Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs 2006;11:137-151
7. Hesketh PJ, Navari RM, Grote T, et al. Double blind randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242-2249
8. Navari RM, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-1248
9. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a selective, 5-hydroxytryptamine receptor antagonist, for the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol 1994;12:2204-2210
10. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995;13:1036-1043
11. Sanger GJ. The involvement of the 5-HT3 receptors in visceral function. In: Central and Peripheral 5-HT¬3 Receptors. London: Academic Press; 1992
12. Roila F, Warr D, Clark-Snow R, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005;13(2):104-108 (Pubitemid 40558165)
13. Lathreille J, Pater J, Johnston D, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 1998;16:1174-1178
14. Navari RM, Madajcwicz S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995;13:2408-2416
15. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000;342:1554-1559
16. Geling O, Eichler H. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-1294
17. Hickok JT, Roscoe JA, Morrow GR, et al. 5-HT3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 2005;6:765-772
18. Rudd JA, Naylor RJ. Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 1994;33:1607-1608
19. Andrews PLR. 5-HT3 receptor antagonists and antiemesis. In: 5-Hydroxytryptamine-3 Receptor Antagonists. Boca Raton (FL)/London: CRC Press; 1994
20. Hesketh PJ. New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer 2004;12:550-554
21. Mantovani G, Maccio A, Aslexandro B, et al. Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer; a randomized controlled trial. Cancer 1996;77:941-948 (Pubitemid 26061290)
22. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol 2003;1:89-103
23. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology. Guideline for Antiemetics in Oncology: update. J Clin Oncol 2006;24:2932-2947
24. ASCO patient guide: preventing nausea and vomiting caused by cancer treatment, 2006. Available from: www.plwc.org [August 2009]
25. The NCCN clinical practice guidelines in oncology, 2009. Available from: www.nccn.org [August 2009]
26. MASCC antiemetic guidelines, 2009. Available from: www.mascc.org [August 2009]
27. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK-1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-410
28. Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000;59:1297-1315
29. Kimura E, Niimi E, Watanabe A, et al. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 1996;23:477-481
30. Taguchi T, Tsukamoto F, Watanabe T, et al. Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 1999;26:1163-1170
31. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18:163-173
32. Perez EA, Navari RM, Kaplan HG, et al. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer 1997;5:31-37
33. Hesketh PJ, Navari RM, Grote T, et al. Double blind randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242-2249
34. Navari RM, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-1339
35. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother 2003;37:1276-1286
36. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-2482
37. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577
38. Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol 2004;15:330-337
39. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-1449
40. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethsone for prevention of nausea and vomting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trial. Lancet Oncol 2009;10:115-124
41. DeJonghe BC, Horn CC. Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). Am J Physiol Regul Integr Comp Physiol 2009;294(4):R902-11
42. Aloxi (palonosetron HCl) injection prescribing information. MGI Pharma, Inc., Bloomington, MN; 2003
43. Cantoreggi S, Parisi S, Van Laar E, et al. Palonosetron, a new 5-HT3 antagonist does not alter antitumor efficacy of various chemotherapeutics in tumor bearing mice [abstract]. Clin Cancer Res 2003;9:6254S
44. Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the Fuctional Living Index-Emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006;4:35-41
45. Cartmell AD, Ferguson S, Yanagihara R, et al. Protection against chemotherapy-induced nausea and vomiting is maintained over multiple cycles of moderately or highly emetogenic chemotherapy by palonosetron, a potent 5-HT3 receptor antagonist. Chicago Proc Am Soc Clin Oncol 2003;756:abstract 3041
46. Yu Z, Liu W, Wang L, et al. The efficacy and safety of palonosetron compared with Granisetron in preventing highly emetogenic chemotherapy-induced vomting in the Chinese cancer patients: a phaseII, multicenter, randimized, comparative clinical trial. Support Care Cancer 2009;17:99102
47. Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5HT3 receptor. Anesth Analg 2008;107:353-355
48. Grote T, Hajdenberg J, Cartmell AD, et al. Palonosetron plus aprepitant and dexamethasone is a highly effective combination to prevent chemotherapy induced nausea and vomting after emetogenic chemotherapy. J Support Oncol 2006;4:403-408
49. Shah A, DeGroot T, Apseloff G. Pharmacokinetic evaluation and safety profile of a 15 minute versus 30 second infusion of palonosetron in healthy subjects. J Clin Pharmacol 2006;46:1139-1145
50. Stoltz R, Cyong J, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5HT3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 2004;44:520-531
51. Aapro MS, Macciocchi A, Gridelli C. Palonosetron improves prevention of chemotherapy induced nausea and vomiting in elderly patients. J Support Oncol 2005;3:55-374
52. Hajdenberg J, Grote T, Yee L, et al. Infusion of palonosetron plus dexamethasone is effective and safe for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol 2006;4:467-471
53. Navari RM, Einhorn LH, Loehrer PJ, et al. A Phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting. Support Care Cancer 2007;15:1285-1291
54. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 2005;13:529-534
55. Einhorn LH, Brames MJ, Dreicer R, et al. Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007;15:1293-1300
56. Navari RM. Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw 2007;5:51-59
57. Musso M, Scalone R, Bonanno V, et al. Plaonosetron and dexamethasone for the Prevention of acute and delayed nausea and vomiting in patients receiving multi-day Chemotherapy. Support Care Cancer 2009;17:205-209
58. Kovac AL, Eberhart L, Kotarski J, et al. A randomized double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg 2008;107:439-444
59. Candiotti KA, Kovac AL, Melson TI, et al. A randomized double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomting. Anesth Analg 2008;107:445-451
60. Bissoli F, McGiuggan M, Bertazzoli M. Post-marketing experience of palonosetron confirms a favorable benefit/risk profile. Support Care Cancer 2005;13(413):A04
61. Hajdenberg J. Safety profile of palonosetron, a pharmacologically distinct 5-HT3 receptor antagonist recently approved for acute and delayed chemotherapy induced nausea [abstract 5770]. Blood 2003;102:510b
62. Morganroth J, Parisi S, Moresino C, et al. High dose palonosetron does not alter parameters including QTC interval in healthy subjects: results of a dose-response, double blind, randomized, parallel E14 study of palonosetron versus moxifloxacin or placebo [abstract 1156]. Eur J Cancer Suppl 2007;5(4):158